Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by pericles1on Apr 04, 2012 6:54pm

275 Views

Post# 19760524

RE: RE: What a Joke!

When they reach 80 patients they open the study up and do analysis, when the last patient is scanned after six weeks they can release the information. This has been discussed in past conference calls. They could announce results when last patient is scanned after six weeks for SD,PR etc. or the debate is weather they will wait 12 for SD,etc.. In the first phase they are not looking for final survival data just initial responses. Then they know to proceed and how many they need to enroll in stage b. Brad has gone into this in great detail in past conference calls.

Bullboard Posts

AI companies to invest in